Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Abstract: Provided herein are compositions of virus like particles (VLPs) of poliovirus (PV) that have one or more stabilizing mutations that confer a higher degree of thermostability to the N-antigenic form of the VLPs. These VLPs are non-infectious, and thus safer for use in vaccine development and administration to clinical subjects.

Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.

Abstract: The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.

Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.

Abstract: Methods for the treatment of cardiac hypertrophy are described. Additionally, the presently disclosed subject matter relates to the use of small molecule compounds for the inhibition of Human antigen R (HuR)-mRNA interaction, and more particularly for the reduction nuclear factor of activated T cells (NFAT) transcriptional activity. Novel methods of screening for small molecule compounds for inhibition of RNA binding proteins interaction with their target RNA (such as HuR-mRNA interactions) or for inhibition of DNA binding proteins to their target DNA are also described.

Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a nitroboronic boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing the nitroboronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.

Abstract: A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electrospinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite phase. The biodegradable fibers may be coated with apatite. When the guided bone regeneration material is immersed in a neutral aqueous solution, silicon species ions are eluted from the calcium carbonate. The guided bone regeneration material excels in bone reconstruction ability.

Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.

Abstract: Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.

Abstract: Provided is a core-shell structure having an excellent immediate effect in transdermal absorption of an active ingredient. A core-shell structure comprising a core portion containing an active ingredient, and a shell portion containing a surfactant having an HLB value of 4 to 14, the core portion being solid, and the surfactant containing a saturated hydrocarbon group having 7 to 15 carbon atoms or an unsaturated hydrocarbon group having 7 to 17 carbon atoms.

Abstract: Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Abstract: A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy.

Abstract: Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1? embedded in the hydrogel, which is useful in treating a myocardial infarction.

Abstract: The present invention provides immediate release abuse resistant or deterrent formulations such as ingestible dosage form articles suitable for the delivery of one or more medicaments or other active materials.

Abstract: The instant disclosure provides cellularized hydrogels containing cells encapsulated in linked polymers of hyaluronic acid, heparin and other components as described herein. Such cellularized hydrogels find use in variety of purposes including effective transplantation of cells into a host organism for cell therapy and the derivation of desired cell types. Other purposes include but are not limited to use as a tissue model for the in vitro study of cellular responses and behaviors. The instant disclosure also provides methods, including methods of making and using the described cellularized hydrogels. Also provided are kits that include components for making and/or using cellularized hydrogels e.g., according to the methods as described herein.

Abstract: The disclosure describes a composition including about 4 weight percent to about 12 weight percent of povidone-iodine complex, about 0.1 weight percent to about 2 weight percent of a tertiary amide, tertiary amide salt, and/or tertiary amide hydrate, about 0.5 weight percent to about 2 weight percent of an emollient with low iodine reactivity, at least one surfactant; and water; wherein the composition has a pH ranging from about 2.0 to about 3.5.

Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.

Abstract: The present invention provides compositions comprising Verteporfin and other anticancer compounds linked to a hydrophilic peptide through a degradable linker molecule to allow the anticancer compounds to penetrate tissues via in situ administration. The compounds of the present invention are useful for sensitizing tumor cells to radiotherapy, preventing recurrence of tumors after surgical resection and for treating remaining unremoved cancer cells at the site of the tumor.

Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with hypomethylating agents.

Abstract: Human anti-human folate receptor beta (FR?) antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat a disorder, including but not limited to inflammatory disorders or cancers expressing cell surface FR?.

Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: A PEG linker as represented by formula (I), wherein n and m are respectively an integer from 1 to 7, providing the PEG linker with 1 to 49 linking sites. A ligand drug conjugate as represented by formula (II). The conjugate uses the PEG linker to increase a drug loading capacity and drug loading diversity, thereby improving pharmaceutical efficacy.

Abstract: The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin®) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.

Abstract: The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.

Abstract: The present disclosure relates to antisense oligonucleotides (AONs) for modulating the expression of glycogen synthase. AONs of the present disclosure may be useful in treating diseases associated with the modulation of the expression of the enzyme glycogen synthase, such as Pompe disease. Also provided by the present disclosure are compositions comprising AONs, as well as methods of down regulating mRNA coding for glycogen synthase, methods for reducing glycogen synthase in skeletal and cardiac muscle, and methods for treating Pompe disease.

Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.

Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

Abstract: Stimuli-responsive NPs with excellent stability, high loading efficiency, encapsulation of multiple agents, targeting to certain cells, tissues or organs of the body, can be used as delivery tools. These NPs contain a hydrophobic inner core and hydrophilic outer shell, which endows them with high stability and the ability to load therapeutic agents with high encapsulation efficiency. The NPs are preferably formed from amphiphilic stimulus-responsive polymers or a mixture of amphiphilic and hydrophobic polymers or compounds, at least one type of which is stimuli-responsive. These NPs can be made so that their cargo is released primarily within target certain cells, tissues or organs of the body, upon exposure to endogenous or exogenous stimuli. The rate of release can be controlled so that it may be a burst, sustained, delayed, or a combination thereof. The NPs have utility as research tools or for clinical applications including diagnostics, therapeutics, or combination of both.

Abstract: The invention provides novel apparatus and methods for efficiently and accurately filling vials with gaseous materials such as a fluorinated gas, with or without concomitantly filling the vials with another liquid or solid material.

Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

Abstract: A hand dryer with a housing in which a cavity accessible from outside through a housing opening is formed for accommodating hands to be dried by means of an airflow, and with a device for generating the airflow, as well as a device for generating UV radiation comprising at least one lamp that emits light in the ultraviolet wavelength range, which is arranged in the housing in such a manner that it emits UV radiation into the cavity. The device for generating UV radiation is designed in such a manner that the UV radiation emitted into the cavity with a wavelength in the range from 228 to 380 nm has a maximum intensity of 20% of the intensity of the UV radiation emitted into the cavity with a wavelength in the range from 200 to 380 nm.

Abstract: The invention provides a method for continuous virus inactivation. The product stream is segmented by introducing a separating medium which is immiscible with the product stream and the segmented product stream is transported into a reactor 1 as detention segment under virus-inactivating conditions for the required detention time.

Abstract: A method for sanitizing biomass in which the biomass is fed to a shaft cooler, and the biomass is heated in the shaft cooler by supplying a heated heating medium to the shaft cooler.

Abstract: Methods and apparatus for sterilization are presented. An apparatus includes a sterilizing cabinet assembly including a cabinet having an access port and a bottom, the bottom configurable to induce a condensate to flow on the bottom to a vent port. The apparatus further includes a door connected to the cabinet, the door moveable between an open position permitting passage through the access port to an interior of the cabinet and a closed position precluding passage through the access port. The apparatus also includes at least one of the cabinet and the door having the vent port, and a filter overlying the vent port and forming a sealed interface with an adjacent portion of the one of the cabinet and the door.

Abstract: Techniques for automatically eradicating microorganisms (e.g., germs, bacteria, and/or viruses) from appliance handles using ultraviolet (UV) light are provided. In one aspect, a system for eradicating biological contaminants from a handle on an appliance door is provided. The system includes a UV light emitter for producing UV disinfecting light during a cleaning cycle; and a waveguide coating on the handle, coupled to the UV light emitter, for propagating the UV disinfecting light over a surface of the handle. The system can also include a control module for controlling the UV light emitter; and at least one sensor for providing data to the control module as to when to initiate or halt a cleaning cycle. A method for eradicating biological contaminants from a handle on an appliance door using the present system is also provided.

Abstract: A sterilization device for sterilizing an object comprises a sterilization chamber defining a treatment zone in which the object for sterilizing is to be positioned; a nitrogen source; a plasma generator in communication with the nitrogen source; and a duct putting the plasma generator into communication with the sterilization chamber and through which a post-discharge stream resulting from a plasma produced by the plasma generator is to flow towards the sterilization chamber. The duct defines an injection orifice for injecting the post-discharge stream into the sterilization chamber. The device has a deflector for deflecting the post-discharge stream and positioned in the sterilization chamber facing a central portion of the injection orifice, upstream from the treatment zone. The deflector is configured to deflect the flow of a central portion of the post-discharge stream as introduced through the central portion of the injection orifice.

Abstract: The present invention relates to a system, and the method of application thereof, for washing and decontamination comprising nebulizing means (8) of a mixture of at least one first gas and at least one first liquid, and pressurizing means (1) of said first gas, wherein said pressurizing means (1) are in fluid communication with a first pressure-regulating valve (3) and with a second pressure-regulating valve (4), the first pressure-regulating valve (3) being in fluid communication with a first pressurized tank (5) through first inlet means (31) of said first gas, the first pressurized tank (5) being configured to contain the first liquid, and comprising first outlet means (30) of said first liquid to the nebulizing means (8) through a first valve (6), at a first pressure that is greater than atmospheric pressure, and wherein the second pressure-regulating valve (4) is in fluid communication with said nebulizing means (8), and is configured to pressurize the gas at a second pressure that is greater than atmosp

Abstract: A monitoring system is disclosed. The monitoring system comprises a range detection system configured for scanning a scene to provide range data, the range data including data describing range to a marker that is detectable by the range detection system and that is placed on a hand of an individual in the scene; and a data processing system configured for processing the range data to identify the marker, to identify the hand based, at least in part on the range to the marker, and to monitor hygienic activity of an individual in the scene.

Abstract: Process monitoring systems include a reader having a read sensor, an optional reference sensor, and a light source. The reader optionally includes an optical block defining an interior volume and an aperture aligned with the read sensor to allow diffuse light to be received by the read sensor. One or more percent reflectance values may be calculated in response to a dark measurement, a correction function, and normalization. The one or more percent reflectance values may be compared to a threshold to determine whether a disinfection cycle was effective. The reader may indicate the determination to a user and provide the determination to a tracking system for diagnostics, inventory management, or compliance monitoring.

Abstract: An illuminator comprising more than one set of ultraviolet radiation sources. A first set of ultraviolet radiation sources operate in a wavelength range of approximately 270 nanometers to approximately 290 nanometers. A second set of ultraviolet radiation sources operate in a wavelength range of approximately 380 nanometers to approximately 420 nanometers. The illuminator can also include a set of sensors for acquiring data regarding at least one object to be irradiated by the first and the second set of ultraviolet radiation sources. A control system configured to control and adjust a set of radiation settings for the first and the second set of ultraviolet radiation sources based on the data acquired by the set of sensors.